| scholarly article | Q13442814 |
| P2093 | author name string | Narender Kumar | |
| Surya Kumar Singh | |||
| Akhilesh Kumar Verma | |||
| Ashish Kumar Gupta | |||
| Jyotsna Kailashiya | |||
| P2860 | cites work | Ca2+ and pH determine the interaction of chromaffin cell scinderin with phosphatidylserine and phosphatidylinositol 4,5,-biphosphate and its cellular distribution during nicotinic-receptor stimulation and protein kinase C activation | Q24642811 |
| Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors | Q34282877 | ||
| Intracellular pH in human and experimental hypertension | Q34360235 | ||
| Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective | Q35174193 | ||
| Signaling events underlying thrombus formation | Q35181664 | ||
| Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling | Q35553368 | ||
| GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes | Q36012529 | ||
| Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein | Q36790211 | ||
| Inhibition of calpain blocks platelet secretion, aggregation, and spreading | Q37307187 | ||
| Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis | Q37400779 | ||
| Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. | Q37825946 | ||
| DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors | Q37869699 | ||
| DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety | Q41867493 | ||
| Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension | Q42502948 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q45212807 | ||
| A key role for dense granule secretion in potentiation of the Ca2+ signal arising from store-operated calcium entry in human platelets | Q45609263 | ||
| Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension | Q46691868 | ||
| Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity | Q46798361 | ||
| Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice | Q46956823 | ||
| Sitagliptin reduces albuminuria in patients with type 2 diabetes. | Q51382706 | ||
| Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. | Q52694276 | ||
| Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes | Q58448492 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 565-570 | |
| P577 | publication date | 2012-09-05 | |
| P1433 | published in | Platelets | Q1573582 |
| P1476 | title | Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. | |
| P478 | volume | 23 |
| Q35914764 | Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus |
| Q38195527 | Antiatherothrombotic effects of dipeptidyl peptidase inhibitors |
| Q38113092 | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes |
| Q38072259 | Cardiovascular effects of gliptins |
| Q92328545 | Coagulatory Defects in Type-1 and Type-2 Diabetes |
| Q38284522 | DPP-4 inhibitors: a patent review (2012 - 2014). |
| Q38976138 | Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events |
| Q38118157 | Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system |
| Q38107546 | Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. |
| Q40294653 | Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis |
| Q33434017 | Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. |
| Q53130761 | Platelets and diabetes: a complex association. |
| Q38175855 | Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus |
| Q38219481 | Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus |
| Q31155491 | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial |
| Q34029715 | The nonglycemic actions of dipeptidyl peptidase-4 inhibitors |
| Q92156078 | Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease |
Search more.